Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 4/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | PRF1 | P14222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918364 | 0.75 | SCN4A (0.52) | CLK4LRRK2 | |
| Hydrochloric Acid SCHEMBL30014721 | 0.73 | SCN4A (0.50) | CLK4LRRK2 | |
| SCHEMBL5067695 | 0.73 | ALDH1A1 (0.54) | CLK4PGRBRD4GSK3ALRRK2 | |
| SCHEMBL4787445 | 0.72 | SCN4A (0.48) | CLK4MAOB | |
| SCHEMBL4716316 | 0.71 | IDO1 (0.51) | CLK4MAOBIDO1XDHPGR | |
| SCHEMBL996127 | 0.70 | ADRA2C (0.64) | CLK4MAOBIDO1XDHCHEK1 | |
| SCHEMBL1456892 | 0.70 | HCAR2 (0.41) | IDO1 | |
| SCHEMBL2154026 | 0.70 | CLK4 (0.65) | CLK4MAOBIDO1XDHPGR | |
| SCHEMBL14955294 | 0.69 | CYP2A6 (0.58) | — | |
| SCHEMBL2674180 | 0.69 | KDM4E (0.55) | CLK4MAOBXDHPGRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284300-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-8927540-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8921357-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| CN-102264727-B | Pyridazinone derivatives | MERCK PATENT GMBH | 2014-11-05 | — | — | CN | disclosed |
| US-8637518-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| CN-101743241-B | Pyridazinone derivates | MERCK PATENT GMBH | 2013-12-25 | — | — | CN | disclosed |
| US-8580781-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184260-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| CN-102264727-A | Pyridazinone derivatives | — | 2011-11-30 | — | — | CN | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| CN-101743241-A | pyridazinone derivates | MERCK PATENT GMBH | 2010-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MET, TYRO3, ERBB2 | CLK4 785/4885MAOB 1013/4885IDO1 749/4885 |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | CLK4 608/4885MAOB 1388/4885IDO1 949/4885 |
| US-20130184260-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | CLK4 609/4885MAOB 1199/4885IDO1 1064/4885 |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | CLK4 609/4885MAOB 1199/4885IDO1 1064/4885 |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | CLK4 677/4885MAOB 1313/4885IDO1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.